The first agents targeting GLP-1 receptor (GLP-1R) signaling were developed to optimize the treatment of type 2 diabetes mellitus (T2D) as an adjunct to metformin when therapeutic goals where not met (Yildirim Simsir et al., 2018). This evidence concerns the gene GLP1R and diabetes mellitus.